Skip to content

Celcuity CELC Non-cash interest expense

Non-cash interest expense at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
Tenet Healthcare logo
Tenet HealthcareTHC

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.28B+1,370%
Enterprise value$4.27B+1,086%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's non-cash interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's non-cash interest expense?
Celcuity (CELC) reported non-cash interest expense of $1.25M in Q1 2026.
How has Celcuity's non-cash interest expense changed year-over-year?
Celcuity's non-cash interest expense increased by 127.2% year-over-year, from $551K to $1.25M.
What is the long-term trend for Celcuity's non-cash interest expense?
Over 3 years (2022 to 2025), Celcuity's non-cash interest expense has grown at a 99.4% compound annual growth rate (CAGR), from $395.76K to $3.14M.